Laura Campogiani, Angela Maria Antonia Crea, Maria Letizia Minardi, Lorenzo Ansaldo, Luigi Coppola, Mirko Compagno, Pietro Vitale, Ilaria Spalliera, Vincenzo Malagnino, Elisabetta Teti, C D'agostini, Chiara Pennacchiotti, Davide Natale Abate, Maria Grazia Celeste, Massimo Andreoni, Marco Iannetta, Loredana Sarmati
BACKGROUND: The objective of this study was to expand real-life data on cefiderocol efficacy to treat multidrug-resistant Acinetobacter baumannii infections. METHODS: This was a retrospective monocentric study including patients hospitalized (>24 hours) at Policlinico Tor Vergata, Rome, Italy, between May 1, 2021, and September 1, 2022, treated with cefiderocol (>48 hours). The primary objective was early clinical improvement at 48-72 hours from cefiderocol start; secondary objectives were clinical success (composite outcome of infection resolution and 14-day survival), breakthrough infection, overall 30-day mortality, and cefiderocol-related adverse events...
December 2023: Open Forum Infectious Diseases